Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | YTHDC1 | Q96MU7 | 4/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | PDE8A | O60658 | 1/20 | 0.42 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30834253 | 1.00 | HPGD (0.47) | HPGDCNR2ADORA2AMEN1KMT2A | |
| SCHEMBL30834254 | 1.00 | HPGD (0.47) | HPGDCNR2ADORA2AMEN1KMT2A | |
| SCHEMBL16774386 | 0.81 | ADORA2A (0.49) | HPGDCNR2ADORA2AMEN1KMT2A | |
| SCHEMBL30834262 | 0.81 | ADORA2A (0.49) | HPGDCNR2ADORA2AMEN1KMT2A | |
| SCHEMBL16774098 | 0.81 | MEN1 (0.55) | HPGDCNR2ADORA2AMEN1KMT2A | |
| SCHEMBL30834223 | 0.79 | NR3C1 (0.48) | HPGDCNR2ADORA2AMEN1KMT2A | |
| SCHEMBL27201578 | 0.79 | NR3C1 (0.48) | HPGDCNR2ADORA2AMEN1KMT2A | |
| SCHEMBL20774516 | 0.75 | HPGD (0.54) | HPGDCNR2ADORA2AMEN1KMT2A | |
| SCHEMBL30552245 | 0.75 | HPGD (0.54) | HPGDCNR2ADORA2AMEN1KMT2A | |
| SCHEMBL3821565 | 0.74 | YTHDC1 (0.57) | HPGDADORA2AMEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | disclosed |
| WO-2024073502-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | GID4, MDM2, XIAP | HPGD 1760/4885CNR2 4592/4885ADORA2A 3968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.